Skip to main content
Wed, Mar 18, 2026
TrendingNews.today
World News
S&P 500 5,142.30 ▲ +0.87%|NASDAQ 16,284.75 ▲ +1.12%|DOW 38,972.10 ▼ -0.23%|AAPL $192.45 ▲ +1.80%|TSLA $241.80 ▼ -2.10%|AMZN $178.92 ▲ +0.54%|GOOGL $141.20 ▲ +0.32%|MSFT $415.60 ▼ -0.15%|
S&P 500 5,142.30 ▲ +0.87%|NASDAQ 16,284.75 ▲ +1.12%|DOW 38,972.10 ▼ -0.23%|AAPL $192.45 ▲ +1.80%|TSLA $241.80 ▼ -2.10%|AMZN $178.92 ▲ +0.54%|GOOGL $141.20 ▲ +0.32%|MSFT $415.60 ▼ -0.15%|
ScienceUnited States2 sourcesNeutral

Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing ...

ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 (Topo 1) inhibitors, commonly used payloads in antibody-drug conjugates (ADCs)

AT
acrivon therapeutics; inc
via Enid News & Eagle - Corroborated by 1 others
ShareRead original

Read the full article at Enid News & Eagle →

Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing ...

Source Verification

Corroboration Score: 2

This story was independently reported by 2 sources. Click any source to read the original article.

Enid News & Eagle
Enid News & Eagle
NewsDataUS
Eagletribune
Eagletribune
NewsDataUS

Comments

0 comments
Be respectful and constructive.
Loading comments...
Previous
Judge orders restoration of Voice of America
Next
Miami Cubans Fear Trump Won’t Go Far Enough: ‘The Castros Have to Go’

Related Articles

Nvidia Details Its Healthcare AI Stack at GTCScience
Nvidia Details Its Healthcare AI Stack at GTC
Hpcwire-21h ago-1 sources
Science
Scientists Discovered Glass Orbs from an Ancient Asteroid Impact. The Crater Is Nowhere to Be Found. - AOL.com
Google News-21h ago-1 sources
Science
Crowd’s Reaction to BuzzFeed’s New AI App: Uncomfortable Laughter
Futurism-21h ago-1 sources